{
    "root": "308dc3a4-51ba-ebd0-e063-6294a90acb99",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PRAVASTATIN SODIUM",
    "value": "20250317",
    "ingredients": [
        {
            "name": "PRAVASTATIN SODIUM",
            "code": "3M8608UQ61"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM OXIDE",
            "code": "3A3U0GI71G"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        }
    ],
    "indications": "therapy lipid-altering agents one component multiple risk factor intervention individuals significantly increased risk atherosclerotic vascular disease due hypercholesterolemia . therapy indicated adjunct diet response diet restricted saturated fat cholesterol nonpharmacologic measures alone inadequate .",
    "contraindications": "adults : recommended starting dose 40 mg daily . 80 mg dose patients reaching ldl-c goal 40 mg. ( 2.2 ) significant renal impairment : recommended starting dose pravastatin 10 mg daily . ( 2.3 ) children ( ages 8 13 years , inclusive ) : recommended starting dose 20 mg daily . ( 2.4 ) adolescents ( ages 14 18 years ) : recommended starting dose 40 mg daily . ( 2.4 )",
    "warningsAndPrecautions": "pravastatin sodium tablets , uspare supplied : 10 mg tablets : white off-white , rounded , rectangular-shaped , biconvex tablets debossed \u201c b 10 \u201d one side plain side . supplied bottles 90 \u2019 count ( ndc 51407-887-90 ) 1000 \u2019 count ( ndc 51407-887-10 ) . bottles contain desiccant canister . 20 mg tablets : white off-white , rounded , rectangular-shaped , biconvex tablets debossed \u201c b 20 \u201d one side plain side . supplied bottles 90 \u2019 count ( ndc 51407-888-90 ) 1000 \u2019 count ( ndc 51407-888-10 ) . bottles contain desiccant canister . 40 mg tablets : white off-white , rounded , rectangular-shaped , biconvex tablets debossed \u201c b 40 \u201d one side plain side . supplied bottles 90 \u2019 count ( ndc 51407-889-90 ) 1000 \u2019 count ( ndc 51407-889-10 ) . bottles contain desiccant canister . 80 mg tablets : white off-white , oval-shaped , biconvex tablets , debossed \u201c b 80 \u201d one side plain side . supplied bottles 90 \u2019 count ( ndc 51407-890-90 ) 1000 \u2019 count ( ndc 51407-890-10 ) . bottles contain desiccant canister .",
    "adverseReactions": "hypersensitivity component medication . ( 4.1 , 6.2 , 11 ) active liver disease unexplained , persistent elevations serum transaminases . ( 4.2 , 5.3 ) pregnancy ( 4.3 , 8.1 , 8.3 ) lactation ( 4.4 , 8.2 )",
    "indications_original": "Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.",
    "contraindications_original": "Adults: the recommended starting dose is 40 mg once daily. Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. (2.2) Significant renal impairment: the recommended starting dose is pravastatin 10 mg once daily. (2.3) Children (ages 8 to 13 years, inclusive): the recommended starting dose is 20 mg once daily. (2.4) Adolescents (ages 14 to 18 years): the recommended starting dose is 40 mg once daily. (2.4)",
    "warningsAndPrecautions_original": "Pravastatin Sodium Tablets, USPare supplied as:\n\n \n                        \n                           10 mg tablets:White to off-white, rounded, rectangular-shaped, biconvex tablets debossed with \u201cB 10\u201d on one side and plain on other side. They are supplied in bottles of 90\u2019s Count (NDC 51407-887-90) and 1000\u2019s Count (NDC 51407-887-10). Bottles contain a desiccant canister.\n\n \n                        \n                           20 mg tablets:White to off-white, rounded, rectangular-shaped, biconvex tablets debossed with \u201cB 20\u201d on one side and plain on other side. They are supplied in bottles of 90\u2019s Count (NDC 51407-888-90) and 1000\u2019s Count (NDC 51407-888-10). Bottles contain a desiccant canister.\n\n \n                        \n                           40 mg tablets:White to off-white, rounded, rectangular-shaped, biconvex tablets debossed with \u201cB 40\u201d on one side and plain on other side. They are supplied in bottles of 90\u2019s Count (NDC 51407-889-90) and 1000\u2019s Count (NDC 51407-889-10). Bottles contain a desiccant canister.\n\n \n                        \n                           80 mg tablets:White to off-white, oval-shaped, biconvex tablets, debossed with \u201cB 80\u201d on one side and plain on other side. They are supplied in bottles of 90\u2019s Count (NDC 51407-890-90) and 1000\u2019s Count (NDC 51407-890-10). Bottles contain a desiccant canister.",
    "adverseReactions_original": "Hypersensitivity to any component of this medication. (4.1, 6.2, 11) Active liver disease or unexplained, persistent elevations of serum transaminases. (4.2, 5.3 ) Pregnancy (4.3, 8.1, 8.3) Lactation (4.4, 8.2)"
}